Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 3/20 | 0.32 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
| ▸ | YAP1 | P46937 | 1/20 | 0.31 |
| ▸ | TEAD4 | Q15561 | 1/20 | 0.31 |
| ▸ | F2 | P00734 | 3/20 | 0.31 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.31 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19974707 | 0.81 | METAP2 (0.36) | METAP2EPHX2YAP1TEAD4EPHX1 | |
| SCHEMBL8055779 | 0.68 | NAAA (0.36) | METAP2EPHX2EPHX1SMN1; SMN2TSHR | |
| SCHEMBL19974902 | 0.67 | ADH1C (0.41) | METAP2EPHX1 | |
| SCHEMBL22132035 | 0.66 | EPHX1 (0.44) | EPHX2EPHX1SMN1; SMN2TSHR | |
| SCHEMBL19982895 | 0.66 | ADH1B (0.38) | — | |
| SCHEMBL19982712 | 0.66 | EPHX1 (0.33) | DPP4EPHX2EPHX1SMN1; SMN2 | |
| SCHEMBL19982886 | 0.64 | NPC1 (0.34) | DPP4EPHX2EPHX1SMN1; SMN2 | |
| SCHEMBL13419170 | 0.63 | NPC1 (0.47) | EPHX1SMN1; SMN2 | |
| SCHEMBL14407371 | 0.62 | EPHX1 (0.40) | EPHX2EPHX1SMN1; SMN2 | |
| SCHEMBL22131907 | 0.61 | MAPK1 (0.40) | EPHX1SMN1; SMN2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018050631-A1 | ANTIVIRAL COMPOUNDS | HAPLOGEN GMBH (AT) | 2018-03-22 | — | — | WO | disclosed |